ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-OR014

Continuation of Statin Therapy Initiated in Pre-ESRD Period and All-Cause and Cardiovascular Mortality after Transition to Dialysis

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 303 CKD: Epidemiology, Outcomes - Cardiovascular


  • Gosmanova, Elvira, Stratton VA Medical Center, Albany, New York, United States
  • Molnar, Miklos Zsolt, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Potukuchi, Praveen Kumar, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Streja, Elani, Harold Simmons Center for Kidney Disease Research and Epidemiology, Orange, California, United States
  • Sumida, Keiichi, Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan
  • Kalantar-Zadeh, Kamyar, University of California Irvine, School of Medicine, Orange, California, United States
  • Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States

De novo statin therapy in ESRD patients failed to demonstrate significant cardiovascular (CV) protection in randomized clinical trials and, therefore, it is not recommended. However, whether continuation of statins from late-stages of non-dialysis dependent CKD to the post-ESRD period is associated with improved all-cause and CV mortality in dialysis patients is unknown.


We identified 14,939 US veterans transitioning to dialysis between 2007-2011 who were receiving statins during the 1 year prior to dialysis initiation and had adequate adherence, defined as proportion of days covered (PDC) of ≥80%. Subsequently, dialysis patients were characterized as statin continuers (N=5,066) if statin therapy was continued with PDC ≥80% during up to 1 year following dialysis initiation, and statin discontinuers (N=9,874) if statins were stopped or adherence to statins was inadequate (PDC <80%). Associations of statin continuation with all-cause and CV mortality following dialysis initiation was examined using Cox regressions adjusted for demographics, comorbidities, medications, and laboratory parameters.


All-cause and CV mortality rates were 285 [95% CI 279-291]/1000 patient-years and 116 [95% CI 112-121]/1000 patient-years, respectively, during a mean ± SD 2.01±1.38 years of follow-up. Statin continuation after ESRD onset was associated with lower all-cause and CV mortality in unadjusted and various adjusted analyses (figure).


Extension of statin therapy following dialysis transition was associated with reduced all-cause and CV mortality. This data support experts’ opinion in the current lipid guidelines that statins started prior to dialysis should be continued after dialysis initiation.


  • NIDDK Support